Esperion announces European Commission approval of the Nilemdo (bempedoic acid) tablet for the treatment of hypercholesterolaemia and mixed dyslipidaemia

Esperion

6 April 2020 - First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients.

Esperion announced today the European Commission approved the Nilemdo (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine. Nilemdo is a first-in-class ATP citrate lyase inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.

The European Commission approved Nilemdo for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Read Esperion press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe